A. Balzano et al., THE SOLUBLE INTERLEUKIN-2 RECEPTOR AS AN INDICATOR OF CLINICAL EVOLUTION IN PATIENTS WITH ULCERATIVE-COLITIS, European journal of gastroenterology & hepatology, 9(2), 1997, pp. 173-177
Background/aims: The soluble interleukin-2 receptor is a useful, non-s
pecific marker of in-vivo activated cellular immune functions. The aim
of this study was to evaluate the correlation between this marker and
clinical evolution of ulcerative colitis. Methods: Serum soluble inte
rleukin-2 receptor levels were determined, by an enzyme immune assay,
in 105 patients affected by ulcerative colitis with different extent a
nd activity of disease. Forty-six of these patients were restaged in a
follow-up study, and their serum-soluble interleukin-2 receptor conce
ntrations were measured again. Results: Serum soluble interleukin-2 re
ceptor level is higher in pan-ulcerative colitis than in left ulcerati
ve colitis (P=0.050) and much higher in active than in quiescent stage
of disease (P=0.029). Clinical relapse of disease is accompanied by a
serum soluble interleukin-2 receptor rise (P=0.0697), whereas clinica
l and histological improvement in disease is accompanied by its signif
icant decrease (P=0.0009). Conclusion: In ulcerative colitis the serum
determination of soluble interleukin-2 receptor is a useful and non-i
nvasive marker of activity, and also extension and evolution of the di
sease.